<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127827">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02005575</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00032069</org_study_id>
    <nct_id>NCT02005575</nct_id>
  </id_info>
  <brief_title>The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade</brief_title>
  <official_title>The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <authority>United States: Cedars Sinai Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a randomized, double-blinded, non-placebo-controlled evaluation of the
      effect of the addition of dexamethasone to intraoperative intercostal nerve block
      bupivicaine solutions on the duration of pain relief and post operative pulmonary function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study proposes two groups of 25 patients undergoing similar VATS surgery with a single
      surgeon, Dr. R. McKenna, who will receive interoperatively placed intercostal nerve blocks
      at the same levels. Each group will receive intercostals nerve blocks with one of two
      different solutions: group one will receive intercostal nerve blocks with only 0.46%
      bupivacaine (19.5 ml of 0.5% bupivacaine + .5 cc saline), group 2 will receive intercostal
      blocks with 0.46% bupivacaine and dexamethasone(19.5 ml of 0.5% bupivacaine + .5ml .4%
      dexamethasone). The patients will have pulmonary lung function objectively assessed by
      portable spirometry and clinical factors both preoperatively and postoperatively. Our study
      objective is to examine and quantify the potentially beneficial effects of intercostal nerve
      blockade prolongation with dexamethasone on postoperative pulmonary function and
      postoperative recovery.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>72 hours post operatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be evaluated for post operative pain using the NRS pain evaulation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Post Minimally Invasive Thorascopic Surgical Pain</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine and Dexamethasone</intervention_name>
    <description>The standard of care is to use a regional block solution containing both decadron and bupivicaine.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 80 years old of either gender, scheduled for unilateral VATS procedure with Dr.
             McKenna for resection of lung tumor.

        Exclusion Criteria:

          -  ASA IV and above

          -  Intolerance, allergy, or contraindication to use of any medications used in this
             study

          -  Significant coronary artery disease (abnormal stress test, myocardial infarction
             within the last 3 months)

          -  Uncontrolled hypertension (BP &gt; 140/90)

          -  History of prior ipsilateral thorascopic surgery

          -  Cardiac arrhythmias particularly prolonged QT syndrome

          -  Drugs known to cause prolonged qT: class IA antiarrhythmics (quinidine, procainamide,
             dysopyramide), class III antiarrhythmics (sotalol, dofetalide, ibutalide,
             amiodarone), haloperidol,  thioridazine, arsenic trioxide, HIV protease inhibitors,
             tricyclic antidepressants

          -  Individuals with significant psychological disorders including: schizophrenia, mania,
             bipolar disorder or psychosis

          -  Pregnant or lactating women

          -  Morbid obesity (BMI &gt; 40 kg/m2) AND/OR weight &gt; 150 kg

          -  Chronic renal failure ( creatinine &gt; 2.0 mg/dL)

          -  Liver failure e.g., active cirrhosis

          -  Alcohol or substance abuse within in the past 3 months

          -  Uncorrected hypokalemia, hypomagnesemia, hypocalcemia (can be due to diuretics,
             mineralocorticoid use, laxatives)

          -  Restrictive lung disease (pulmonary fibrosis, myasthenia gravis) or FEV1 or FEV less
             than 70% of predicted value.

          -  Type 2 diabetes

          -  Neuropathic pain

          -  Chronic opioid consumption (&gt;30mg oxycodone or greater per day)

          -  Cahexia from any cause

          -  systemic use of corticosteroids for greater than 2 weeks in the 6 months prior to
             surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>dermot Maher</investigator_full_name>
    <investigator_title>Resident Department of Anesthesia</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
